Oral treatment for multiple sclerosis

  title={Oral treatment for multiple sclerosis},
  author={J. Killestein and R. Rudick and C. Polman},
  journal={The Lancet Neurology},
  • J. Killestein, R. Rudick, C. Polman
  • Published 2011
  • Medicine
  • The Lancet Neurology
  • BACKGROUND The armamentarium for the treatment of relapsing-remitting multiple sclerosis (RRMS) is increasing rapidly. Several oral treatments have shown benefit and will generate much interest because of the convenience of such administration. However, availability of convenient oral drugs will not necessarily translate into clinical effectiveness and safety. Here, we provide an interim report about the mechanisms of action, and efficacy and safety results that have been reported since January… CONTINUE READING
    98 Citations
    Role of oral teriflunomide in the management of multiple sclerosis
    • 12
    • Highly Influenced
    • PDF
    Oral Disease-Modifying Therapies for Multiple Sclerosis
    • 33
    • PDF
    An update on cladribine for relapsing-remitting multiple sclerosis
    • 11
    Current and Future Therapies for Multiple Sclerosis
    • 63
    • PDF
    Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
    • 9
    • PDF


    Oral Therapies for Multiple Sclerosis
    • 30
    Emerging Oral Therapies for Multiple Sclerosis
    • C. E. Miller, M. Umhauer
    • Medicine
    • The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
    • 2011
    • 35
    Multiple sclerosis therapies: molecular mechanisms and future.
    • 22
    Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    • 748
    • PDF
    Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    • 1,792
    • PDF